Tivic Health Systems, Inc. (NASDAQ: TIVC)

Tivic Health Systems, Inc., often known as Tivic Health, is a company that operates in the health technology sector, specializing in bioelectronic medicine. This branch of the global neuromodulation market focuses on treating various diseases and conditions by modulating the electrical signals carried along nerve pathways, without the use of traditional implanted technology. Tivic Health has developed two non-invasive bioelectronic platforms that deliver therapeutic benefits through the manipulation of these signals.

The company's first commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic's existing product, ClearUP Sinus Pain Relief. ClearUP is marketed for the treatment of sinus pain and congestion, utilizing ultra-low current electrical waves to relieve symptoms prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu, and other disease conditions. The product has received FDA approval for the treatment of sinus pain and congestion and has also received CE Mark approval for international marketing.

Tivic's second platform is a research-stage platform directed to vagus nerve stimulation, which is currently undergoing clinical evaluation. The vagus nerve is the tenth cranial nerve and the longest autonomic nerve in the body, responsible for regulating several bodily functions. Modulating activity in this nerve pathway is of significant interest in academic research and industry, and Tivic's non-invasive approach has the potential to accelerate new product development.

Tivic's technology combines proprietary algorithms, programmable stimulation parameters, and a patented monopolar delivery mechanism to modulate nerve signals. Key technical features include treatment point detection, monopolar circuit, proprietary waveform delivery, and ergonomic design and ease of use. The company has issued several patents related to its technology, including US10625076, US11160978, and US10537738.

Tivic's competitive landscape is characterized by pharmaceutical treatments, such as analgesic medications, antihistamine medications, and oral and intranasal decongestants, which often have side effects and limited efficacy. Non-pharmaceutical treatments, such as nasal irrigation and bioelectronic devices, are also available, but may not be as effective or convenient as Tivic's ClearUP product.

Tivic's clinical research has demonstrated the safety and efficacy of ClearUP Sinus Relief in treating sinus pain from allergic rhinitis and moderate to severe congestion. Two separate clinical trials have shown that ClearUP reduces sinus pain and congestion symptoms rapidly and clinically meaningfully, with a magnitude of change equivalent to efficacy seen in studies of fluticasone propionate after two weeks of use.

Tivic's research initiatives are focused on developing new product candidates, including npdPP, an at-home use device for treating postoperative pain after sinus surgery, and npdMI, an at-home use device for treating migraine headaches. The company is also exploring the clinical utility of its stimulation approach for other clinical conditions, including chronic quality-of-life conditions, severe life-altering conditions, and acute conditions.

In terms of component sourcing and manufacturing, Tivic's ClearUP device is comprised of conventional, off-the-shelf electronic components, with certain components sourced primarily from China. To increase predictability in sourcing and pricing of electronic components, the company maintains an agreement with Future Electronics.

Tivic Health Systems' intellectual property portfolio currently consists of six issued U.S. patents, 22 patents pending in the U.S. and abroad, seven trademarks granted in the U.S. and China, and two trademark applications filed in the U.S. The company believes that each of these assets, in addition to its intellectual property and regulatory clearances, will create barriers to entry for competitors.

Tivic's products are subject to regulation by the FDA, which classifies medical devices into three classes based on the degree of risk associated with a device and the level of regulatory control deemed necessary to ensure its safety and effectiveness. The company's ClearUP Sinus Relief is a Class II medical device that has received FDA clearance and CE Mark approval.

The company's operations are also subject to various federal and state laws and regulations, including the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Federal Food, Drug, and Cosmetic Act (FD&C Act), and the California Consumer Privacy Act (CCPA). Tivic believes that it is in material compliance with these laws and regulations, but there can be no assurance that it will not be subject to fines, penalties, or other adverse consequences if it fails to comply with these laws and regulations in the future.